Ozempic Maker Novo Nordisk to Cut 9,000 Jobs

Novo Nordisk will cut 9,000 jobs (11% of workforce), including 5,000 in Denmark, marking the largest layoff in Danish history.
The layoffs are expected to save 8 billion Danish kroner ($1.25–1.3 billion) annually, some of which will be reinvested in research, development, manufacturing, and global patient access.
Novo Nordisk lowered its 2025 operating profit growth forecast to 4–10%, down from 19–27% range it forecast at the beginning of the year.
The company faces rising competition from Eli Lilly and copycat drugs in the U.S., impacting sales of Wegovy and Ozempic.
Novo Nordisk’s workforce had nearly doubled from 43,700 in 2020 to 78,400 today during a period of rapid expansion fueled by the popularity of its obesity drugs.

No results